ELOVL3 CRISPR/Cas9 KO Plasmid (h): sc-407282
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ELOVL3 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ELOVL3 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ELOVL3 CRISPR/Cas9 KO Plasmid (h) | sc-407282 | 20 µg | $397.00 |
Overview
ELOVL3 (elongation of very long chain fatty acids protein 3) is an endoplasmic reticulum–localized elongase that catalyzes the extension of saturated and monounsaturated fatty acyl-CoAs to generate very long-chain fatty acids used in complex lipid biosynthesis. Through its role in fatty acid elongation, ELOVL3 contributes to lipid homeostasis, membrane composition, and formation of lipid-derived signaling and storage pools that influence cellular metabolism. ELOVL3 activity is linked to lipid metabolic programs in tissues with high lipid turnover, and dysregulation of elongation pathways is frequently studied in the context of metabolic imbalance and lipid-associated cellular stress. Altered very long-chain fatty acid composition can impact organelle function and inflammatory signaling, making ELOVL3 a relevant node for mechanistic studies of lipid metabolism–associated phenotypes.
ELOVL3 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ELOVL3 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ELOVL3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ELOVL3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ELOVL3 protein expression.
This CRISPR knockout system enables efficient generation of ELOVL3-deficient cell models for investigation of ELOVL3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting ELOVL3 exon(s) critical for ELOVL3 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple ELOVL3 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by ELOVL3 CRISPR/Cas9 KO Plasmid (h) and ELOVL3 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the ELOVL3 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by ELOVL3 HDR Plasmid (h) and ELOVL3 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by ELOVL3 homology arms to support homology-directed repair at defined ELOVL3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.